The Newsroom

Investigations  /  02.04.2019

Shareholder investigation of DBV Technologies

DBV Technologies S.A. (DBVT) Accused of Misleading Investors About the Efficacy of Its Drug

According to the complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between February 14, 2018 and December 19, 2018, in February 2018, DBV Technologies S.A. (DBVT) announced that the U.S. Food and Drug Administration (“FDA”) agreed that the efficacy and safety data for DBV’s drug, Viaskin Peanut, supported the submission of a Biologics License Application (“BLA”). In October 2018, DBV stated that the company submitted its BLA, calling it a “significant step forward for those families living with peanut allergy.” It came as a surprise to investors when, less than two months later, DBV announced that it voluntarily withdrew its BLA because the FDA determined that the level of detail for manufacturing procedures and quality controls was insufficient. On this news, DBV shares plummeted nearly 60% to close at $5.76 per share on December 20, 2018.

DBV Technologies S.A. (DBVT) Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can please send us a message via the Shareholder Information form below.

Shareholder Information

  • Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

How can we help you?

CONTACT US TODAY | 1-800-350-6003 or info@robbinsarroyo.com

Tell us your concerns